PDS Biotechnology Corp Research and Development Expense
PDS Biotechnology Corp (PDSB) reported Research and Development Expense of $3.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- PDS Biotechnology Corp research and development expense for the quarter ending 2026-06-30 was $3.27M, a 22.49% decline year-over-year.
- PDS Biotechnology Corp research and development expense for the quarter ending 2026-03-31 was $3.46M, a 40.71% decline year-over-year.
- PDS Biotechnology Corp research and development expense for the quarter ending 2025-12-31 was $4.41M, a 2.74% decline year-over-year.
- PDS Biotechnology Corp research and development expense for the quarter ending 2025-09-30 was $4.58M, a 32.74% decline year-over-year.
- PDS Biotechnology Corp research and development expense for fiscal 2025 was $19.03M, a 15.69% decline from fiscal 2024.
- PDS Biotechnology Corp research and development expense for fiscal 2024 was $22.57M, a 18.72% decline from fiscal 2023.
- PDS Biotechnology Corp research and development expense for fiscal 2023 was $27.76M, a 5.67% decline from fiscal 2022.
- PDS Biotechnology Corp research and development expense for fiscal 2022 was $29.43M, a 161.50% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.27M 10-Q · filed 2026-08-13 | $6.72M 10-Q · filed 2026-08-13 | $11.13M derived: sum of 3 quarters · filed 2026-08-13 | $15.70M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $3.46M 10-Q · filed 2026-05-14 | $7.86M derived: sum of 2 quarters · filed 2026-05-14 | $12.44M derived: sum of 3 quarters · filed 2026-05-14 | $16.65M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $8.98M derived: sum of 2 quarters · filed 2026-03-30 | $13.19M derived: sum of 3 quarters · filed 2026-08-13 | $19.03M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $4.58M 10-Q · filed 2025-11-13 | $8.79M derived: sum of 2 quarters · filed 2026-08-13 | $14.62M 10-Q · filed 2025-11-13 | $19.15M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $4.21M 10-Q · filed 2026-08-13 | $10.04M 10-Q · filed 2026-08-13 | $14.57M derived: sum of 3 quarters · filed 2026-08-13 | $21.38M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $5.83M 10-Q · filed 2026-05-14 | $10.36M derived: sum of 2 quarters · filed 2026-05-14 | $17.16M derived: sum of 3 quarters · filed 2026-05-14 | $21.69M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $11.33M derived: sum of 2 quarters · filed 2026-03-30 | $15.86M derived: sum of 3 quarters · filed 2026-03-30 | $22.57M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $6.80M 10-Q · filed 2025-11-13 | $11.33M derived: sum of 2 quarters · filed 2025-11-13 | $18.04M 10-Q · filed 2025-11-13 | $25.50M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $4.53M 10-Q · filed 2025-08-13 | $11.23M 10-Q · filed 2025-08-13 | $18.70M derived: sum of 3 quarters · filed 2025-08-13 | $25.15M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $6.70M 10-Q · filed 2025-05-14 | $14.17M derived: sum of 2 quarters · filed 2025-05-14 | $20.62M derived: sum of 3 quarters · filed 2025-05-14 | $28.62M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $7.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $13.91M derived: sum of 2 quarters · filed 2025-03-27 | $21.92M derived: sum of 3 quarters · filed 2025-03-27 | $27.76M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $6.45M 10-Q · filed 2024-11-14 | $14.45M derived: sum of 2 quarters · filed 2024-11-14 | $20.30M 10-Q · filed 2024-11-14 | $36.45M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $8.00M 10-Q · filed 2024-08-13 | $13.85M 10-Q · filed 2024-08-13 | $30.00M derived: sum of 3 quarters · filed 2024-08-13 | $34.36M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $5.84M 10-Q · filed 2024-05-15 | $22.00M derived: sum of 2 quarters · filed 2024-05-15 | $26.35M derived: sum of 3 quarters · filed 2024-05-15 | $30.11M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $16.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $20.51M derived: sum of 2 quarters · filed 2024-03-28 | $24.27M derived: sum of 3 quarters · filed 2024-03-28 | $29.43M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $4.35M 10-Q · filed 2023-11-14 | $8.11M derived: sum of 2 quarters · filed 2023-11-14 | $13.28M 10-Q · filed 2023-11-14 | $16.67M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $3.76M 10-Q · filed 2023-08-14 | $8.92M 10-Q · filed 2023-08-14 | $12.31M derived: sum of 3 quarters · filed 2023-08-14 | $16.00M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $5.16M 10-Q · filed 2023-05-15 | $8.55M derived: sum of 2 quarters · filed 2023-05-15 | $12.24M derived: sum of 3 quarters · filed 2023-05-15 | $15.00M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $3.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $7.08M derived: sum of 2 quarters · filed 2023-03-28 | $9.84M derived: sum of 3 quarters · filed 2023-03-28 | $11.25M 10-K · filed 2023-03-28 | ||||
| 2021-09-30 | $3.69M 10-Q · filed 2022-11-14 | $6.45M derived: sum of 2 quarters · filed 2022-11-14 | $7.87M 10-Q · filed 2022-11-14 | $10.34M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $2.76M 10-Q · filed 2022-08-08 | $4.18M 10-Q · filed 2022-08-08 | $6.65M derived: sum of 3 quarters · filed 2022-08-08 | $8.72M derived: sum of 4 quarters · filed 2022-08-08 | ||||
| 2021-03-31 | $1.41M 10-Q · filed 2022-05-11 | $3.89M derived: sum of 2 quarters · filed 2022-05-11 | $5.95M derived: sum of 3 quarters · filed 2022-05-11 | $7.37M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2020-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $4.54M derived: sum of 2 quarters · filed 2022-03-31 | $5.95M derived: sum of 3 quarters · filed 2022-03-31 | $7.92M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $2.06M 10-Q · filed 2021-11-10 | $3.48M derived: sum of 2 quarters · filed 2021-11-10 | $5.45M 10-Q · filed 2021-11-10 | $6.79M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $1.41M 10-Q · filed 2021-08-12 | $3.39M 10-Q · filed 2021-08-12 | $4.73M derived: sum of 3 quarters · filed 2021-08-12 | $6.57M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $1.97M 10-Q · filed 2021-05-13 | $3.32M derived: sum of 2 quarters · filed 2021-05-13 | $5.15M derived: sum of 3 quarters · filed 2021-05-13 | $7.04M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $3.18M derived: sum of 2 quarters · filed 2021-03-18 | $5.07M derived: sum of 3 quarters · filed 2021-03-18 | $6.10M 10-K · filed 2021-03-18 | ||||
| 2019-09-30 | $1.83M 10-Q · filed 2020-11-13 | $3.72M derived: sum of 2 quarters · filed 2020-11-13 | $4.75M 10-Q · filed 2020-11-13 | $5.02M derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2019-06-30 | $1.89M 10-Q · filed 2020-08-13 | $2.92M 10-Q · filed 2020-08-13 | $3.18M derived: sum of 3 quarters · filed 2020-08-13 | $3.38M derived: sum of 4 quarters · filed 2020-08-13 | ||||
| 2019-03-31 | $1.03M 10-Q · filed 2020-05-13 | $1.30M derived: sum of 2 quarters · filed 2020-05-13 | $1.49M derived: sum of 3 quarters · filed 2020-05-13 | $1.66M derived: sum of 4 quarters · filed 2020-05-13 | ||||
| 2018-12-31 | $266.93K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $461.00K derived: sum of 2 quarters · filed 2020-03-27 | $629.61K derived: sum of 3 quarters · filed 2020-03-27 | $830.74K 10-K · filed 2020-03-27 | $16.07M 10-K · filed 2019-02-21 | |||
| 2018-09-30 | $194.07K 10-Q · filed 2019-11-07 | $317.68K 10-Q · filed 2018-11-01 | $362.67K derived: sum of 2 quarters · filed 2019-11-07 | $563.81K 10-Q · filed 2019-11-07 | $15.58M 10-Q · filed 2018-11-01 | $11.40M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2018-06-30 | $168.61K 10-Q · filed 2019-08-01 | $2.52M 10-Q · filed 2018-08-01 | $369.74K 10-Q · filed 2019-08-01 | $15.27M 10-Q · filed 2018-08-01 | $11.20M derived: sum of 3 quarters · filed 2019-08-01 | $18.12M derived: sum of 4 quarters · filed 2019-08-01 | ||
| 2018-03-31 | $201.14K 10-Q · filed 2019-05-14 | $12.74M 10-Q · filed 2018-05-01 | $11.03M derived: sum of 2 quarters · filed 2019-05-14 | $17.95M derived: sum of 3 quarters · filed 2019-05-14 | $26.92M derived: sum of 4 quarters · filed 2019-05-14 | |||
| 2017-12-31 | $10.83M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $17.75M derived: sum of 2 quarters · filed 2019-02-21 | $26.72M derived: sum of 3 quarters · filed 2019-02-21 | $34.31M 10-K · filed 2019-02-21 | ||||
| 2017-09-30 | $6.91M 10-Q · filed 2018-11-01 | $15.89M derived: sum of 2 quarters · filed 2018-11-01 | $23.48M 10-Q · filed 2018-11-01 | $30.26M derived: sum of 4 quarters · filed 2018-11-01 | ||||
| 2017-06-30 | $8.98M 10-Q · filed 2018-08-01 | $16.56M 10-Q · filed 2018-08-01 | $23.34M derived: sum of 3 quarters · filed 2018-08-01 | $30.07M derived: sum of 4 quarters · filed 2018-08-01 | ||||
| 2017-03-31 | $7.59M 10-Q · filed 2018-05-01 | $14.37M derived: sum of 2 quarters · filed 2018-05-01 | $21.09M derived: sum of 3 quarters · filed 2018-05-01 | $27.07M derived: sum of 4 quarters · filed 2018-05-01 | ||||
| 2016-12-31 | $6.78M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $13.50M derived: sum of 2 quarters · filed 2018-03-01 | $19.48M derived: sum of 3 quarters · filed 2018-03-01 | $24.83M 10-K · filed 2018-03-01 | ||||
| 2016-09-30 | $6.72M 10-Q · filed 2017-11-01 | $12.70M derived: sum of 2 quarters · filed 2017-11-01 | $18.05M 10-Q · filed 2017-11-01 | $23.31M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $5.98M 10-Q · filed 2017-08-01 | $11.32M 10-Q · filed 2017-08-01 | $16.59M derived: sum of 3 quarters · filed 2018-03-01 | $23.10M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-03-31 | $5.35M 10-Q · filed 2017-05-03 | $10.61M derived: sum of 2 quarters · filed 2018-03-01 | $17.12M derived: sum of 3 quarters · filed 2018-03-01 | $20.32M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-12-31 | $5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $11.77M derived: sum of 2 quarters · filed 2018-03-01 | $14.97M derived: sum of 3 quarters · filed 2018-03-01 | $17.84M 10-K · filed 2018-03-01 | ||||
| 2015-09-30 | $6.51M 10-Q · filed 2016-11-01 | $9.70M derived: sum of 2 quarters · filed 2016-11-01 | $12.57M 10-Q · filed 2016-11-01 | $15.41M derived: sum of 4 quarters · filed 2017-03-02 | ||||
| 2015-06-30 | $3.20M 10-Q · filed 2016-08-03 | $6.07M 10-Q · filed 2016-08-03 | $8.90M derived: sum of 3 quarters · filed 2017-03-02 | $11.32M derived: sum of 4 quarters · filed 2017-03-02 | ||||
| 2015-03-31 | $2.87M 10-Q · filed 2016-05-03 | $5.71M derived: sum of 2 quarters · filed 2017-03-02 | $8.13M derived: sum of 3 quarters · filed 2017-03-02 | |||||
| 2014-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $5.26M derived: sum of 2 quarters · filed 2017-03-02 | $8.47M 10-K · filed 2017-03-02 | |||||
| 2014-09-30 | $2.42M 10-Q · filed 2015-11-06 | $5.64M 10-Q · filed 2015-11-06 | ||||||
| 2013-12-31 | $4.48M 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |